JPRN-jRCT2080220416未知3 期
A study of R435 (Bevacizumab) in Combination With R340 (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
适应症
试验速览
- 阶段
- 3 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Inclusin criteria:
- •- adult patients, >=18 years of age
- •- inoperable, locally advanced or metastatic cancer of stomach or gastro-esophageal junction
- •- measurable or non-measurable but evaluable disease
- •- ECOG PS of 0, 1 or 2
- •Exclusion criteria:
- •- previous chemotherapy for locally advanced or metastatic gastric cancer
- •- previous platinum or anti-angiogenic therapy
- •- patients with locally advanced disease who are candidates for curative therapy
- •- radiotherapy within 28 days of randomisation
- •- evidence of CNS metastasis
- •- inadequate organ function
- •- history of bleeding or wound-healing complications
排除标准
- 未提供
研究者
相似试验
未知
3 期
Safety comformation study of R435 (Bevacizumab) in patients with metastatic colorectal cancerMetastatic colorectal cancerJPRN-jRCT2080220205Chugai Pharmaceutical Co., Ltd.
未知
3 期
A compassionate use study of R435(Bevacizumab) in chemotherapy naive and inoperable malignant pleural mesothelioma patientschemotherapy naive and inoperable malignant pleural mesotheliomaJPRN-jRCT2080223406CHUGAI PHARMACEUTICAL CO., LTD.12
未知
1 期
Phase I/II study of R435 (Bevacizumab) in patients with metastatic colorectal cancerMetastatic colorectal cancerJPRN-jRCT2080220022Chugai Pharmaceutical Co., Ltd.
未知
3 期
A study of R435(Bevacizmab) Added to Various Chemotherapy Regimens in Patients With Colon CancerColon cancerJPRN-jRCT2080220307Chugai Pharmaceutical Co., Ltd.
未知
2 期
Phase II clinical study of R435 (bevacizumab) in combination with paclitaxel in patients with inoperable metastatic breast cancerInoperable metastatic breast cancerJPRN-jRCT2080220385Chugai Pharmaceutical Co., Ltd.